Pfizer Corporation

Matthew Forrest Sammons

Qingyi Yang

Dafydd Rhys Owen

Jamison Bryce Tuttle

Matthew Richard Reese

Robert L Dow

David Andrew Griffith

Patrick Robert Verhoest

Robert Steven Kania

Philip Albert Carpino

Roger B Ruggeri

Christopher Ryan Butler

David Hepworth

Matthew Scott Dowling

Cynthia Louise Palmer

Christopher John Helal

Martin Youngjin Pettersson

Joseph Scott Warmus

Xiaojing Yang

Aaron Smith

Daniel Wei-Shung Kung

Jana Polivkova

Michelle Renee Garnsey

Edward L Conn

Suvi Orr

Benjamin N Rocke

Yan Zhang

Kevin Alexander Ogilvie

Liuqing Wei

Kimberly O Cameron

Robert Louis Hoffman

Samit Kumar Bhattacharya

Sajiv Krishnan Nair

Liying Zhang

Kevin Daniel Freeman-Cook

Eugene Yuanjin Rui

Mehran Jalaie

John M Curto

Brian Kenneth Raymer

Ping Chen

Douglas Carl Behenna

Suman Luthra

Samir Kulkarni

Anil Mahadeo Rane

Yajing Lian

Klimentina Dimitrova Pencheva

Jonathan Richard Lillis

Martyn David Ticehurst

Matthew Nathan O'Brien Laramy

Bradley Paul Sullivan

Andrew John Thiel

Padmavani Bezawada

Rohit Jaini

Emma Louise Hawking

Aaron Christopher Smith

The invention relates to compounds of formula I wherein Rand Rare as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-COV-2 with the compound.

Compounds and method of treating COVID-19

Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:

Methods for antagonizing a melanocortin 4 receptor

The invention relates to compounds of formula I wherein R, Rand - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Compounds and methods for the treatment of COVID-19

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R, R, R, X, Y, Y, Y, Yand Yare defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

Melanocortin 4 receptor antagonists and uses thereof

The invention relates to compounds of Formula I&#x2033; wherein R, R, R, R, p, q and q' are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.

Nitrile-containing antiviral compounds

This invention relates to compounds of general Formula I in which A, R, R, Rand Rare as defined herein, and the pharmaceutically acceptable salts thereof; to pharmaceutical compositions comprising such compounds and salts; to methods of using such compounds, salts and compositions for treating pulmonary hypertension and related diseases, like pulmonary arterial hypertension; to methods of using such compounds, salts and compositions for treating abnormal cell growth, such as cancer; and to processes to make such compounds, salts and compositions.

Anti-proliferative agents for treating PAH

Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.

2-thiopyrimidinones

Growing community of inventors

Quincy, MA, United States of America

Matthew Forrest Sammons